- Home
- PPT vs ATAI Comparison
PPT vs ATAI Comparison
Compare PPT & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPT
- ATAI
- Stock Information
- Founded
- PPT 1988
- ATAI 2018
- Country
- PPT United States
- ATAI Germany
- Employees
- PPT N/A
- ATAI N/A
- Industry
- PPT Finance Companies
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- PPT Finance
- ATAI Health Care
- Exchange
- PPT Nasdaq
- ATAI Nasdaq
- Market Cap
- PPT 335.4M
- ATAI 282.6M
- IPO Year
- PPT N/A
- ATAI 2021
- Fundamental
- Price
- PPT $3.66
- ATAI $2.41
- Analyst Decision
- PPT
- ATAI Strong Buy
- Analyst Count
- PPT 0
- ATAI 3
- Target Price
- PPT N/A
- ATAI $10.50
- AVG Volume (30 Days)
- PPT 156.1K
- ATAI 2.9M
- Earning Date
- PPT 01-01-0001
- ATAI 05-14-2025
- Dividend Yield
- PPT 8.84%
- ATAI N/A
- EPS Growth
- PPT N/A
- ATAI N/A
- EPS
- PPT N/A
- ATAI N/A
- Revenue
- PPT N/A
- ATAI $1,863,000.00
- Revenue This Year
- PPT N/A
- ATAI $554.22
- Revenue Next Year
- PPT N/A
- ATAI N/A
- P/E Ratio
- PPT N/A
- ATAI N/A
- Revenue Growth
- PPT N/A
- ATAI 572.56
- 52 Week Low
- PPT $3.25
- ATAI $1.03
- 52 Week High
- PPT $3.72
- ATAI $2.64
- Technical
- Relative Strength Index (RSI)
- PPT 52.04
- ATAI 69.52
- Support Level
- PPT $3.66
- ATAI $2.18
- Resistance Level
- PPT $3.73
- ATAI $2.56
- Average True Range (ATR)
- PPT 0.04
- ATAI 0.22
- MACD
- PPT -0.00
- ATAI 0.03
- Stochastic Oscillator
- PPT 56.19
- ATAI 76.53
About PPT Putnam Premier Income Trust
Putnam Premier Income Trust is a Massachusetts business trust operating as a non-diversified closed-end management investment company. The fund is currently operating as a diversified fund. Its investment objective is to seek high current income consistent with the preservation of capital by allocating its investments to the U.S. government sector.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.